News headlines about Apricus Biosciences (NASDAQ:APRI) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apricus Biosciences earned a news impact score of 0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.3385252095517 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

APRI has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Apricus Biosciences in a research note on Wednesday, August 30th. Zacks Investment Research raised Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Tuesday, October 31st.

Shares of Apricus Biosciences (APRI) traded down $0.03 during mid-day trading on Friday, hitting $1.70. The stock had a trading volume of 67,100 shares, compared to its average volume of 626,643. Apricus Biosciences has a 12 month low of $0.86 and a 12 month high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.15). During the same quarter in the prior year, the business earned ($0.19) earnings per share. sell-side analysts expect that Apricus Biosciences will post -0.6 EPS for the current year.

WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Apricus Biosciences (APRI) Share Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-apricus-biosciences-apri-share-price.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Insider Buying and Selling by Quarter for Apricus Biosciences (NASDAQ:APRI)

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.